Omega Therapeutics Announced Presentation Of New Preclinical Data Demonstrating Durable, Tunable Bidirectional Regulation Of Gene Expression In Cellular Models At Pre-transcriptional Level At The American Society Of Gene And Cell Therapy Annual Meeting

5/8/24 7:13:16 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $OMGA alert in real time by email

Get the next $OMGA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$OMGA

Date	Price Target	Rating	Analyst
11/15/2024		Outperform → Mkt Perform	Raymond James
6/18/2024	$12.00	Outperform	Raymond James
5/25/2023	$18.00 → $15.00	Buy	Jefferies
12/8/2022	$11.00	Buy	H.C. Wainwright
9/23/2022	$12.00	Buy	Chardan Capital Markets
8/24/2021	$36.00	Outperform	Wedbush
8/24/2021	$30.00	Buy	Jefferies
8/24/2021	$30.00	Overweight	Piper Sandler

More analyst ratings

Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies
CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, today announced that Angela Hwang, MBA, will join Flagship Pioneering as CEO-Partner, and Metaphore as Chief Executive Officer, effective January 1, 2025. Most recently, Hwang served as Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer. During her tenure at Pfizer, Hwang helped brin
11/20/24 8:00:00 AM ET
$FHTX
$MRNA
$OMGA
$SANA
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results
Established clinical proof-of-mechanism and validation of epigenomic controllers as potential new class of medicines from completed Phase 1 MYCHELANGELO™ I trial for c-MYC in HCC; Company exploring strategic partnership opportunities for Phase 2 development of OTX-2002Company is focusing capital resources on three prioritized programs that reflect Omega's unique value proposition to enable precision epigenomic control for potential therapeutic advantages versus existing modalitiesBoard has appointed Kaan Certel, Ph.D., as Omega's President and Chief Executive Officer, and Jennifer Nelson, Ph.D., as Chief Scientific OfficerCompany is pursuing strategic partnership opportunities to support dev
11/14/24 4:05:00 PM ET
$OMGA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio
Williams was promoted from Operating Partner at Flagship Pioneering and President at Apriori Bio Apriori Bio has made significant progress in 2024, including securing a collaboration with CEPI, assembling a world class board of directors and building out an early pipeline of prospective vaccines CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Apriori Bio, a biotechnology company aimed at providing humanity with variant-resilient protection against rapidly-evolving viruses, today announced that Craig Williams, MBA, has been promoted to CEO-Partner at Flagship Pioneering and Chief Executive Officer of Apriori.
11/13/24 8:00:00 AM ET
$FHTX
$MRNA
$OMGA
$SANA
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)

$OMGA
Press Releases

Fastest customizable press release news feed in the world

Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies
CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, today announced that Angela Hwang, MBA, will join Flagship Pioneering as CEO-Partner, and Metaphore as Chief Executive Officer, effective January 1, 2025. Most recently, Hwang served as Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer. During her tenure at Pfizer, Hwang helped brin
11/20/24 8:00:00 AM ET
$FHTX
$MRNA
$OMGA
$SANA
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer
Ampersand's AND™ Platform will be used to identify programmed biologics for the treatment of obesity-related targets Montai's CONECTA™ AI platform will be used to identify small molecules directed to a potential Non-Small Cell Lung Cancer-related target Collaborations will leverage Pfizer's deep expertise in early discovery and development for cardiometabolic and cancer treatments, two priority therapeutic areas for the company CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further dev
11/20/24 6:30:00 AM ET
$FHTX
$MRNA
$OMGA
$SANA
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results
Established clinical proof-of-mechanism and validation of epigenomic controllers as potential new class of medicines from completed Phase 1 MYCHELANGELO™ I trial for c-MYC in HCC; Company exploring strategic partnership opportunities for Phase 2 development of OTX-2002Company is focusing capital resources on three prioritized programs that reflect Omega's unique value proposition to enable precision epigenomic control for potential therapeutic advantages versus existing modalitiesBoard has appointed Kaan Certel, Ph.D., as Omega's President and Chief Executive Officer, and Jennifer Nelson, Ph.D., as Chief Scientific OfficerCompany is pursuing strategic partnership opportunities to support dev
11/14/24 4:05:00 PM ET
$OMGA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Omega Therapeutics Announced Presentation Of New Preclinical Data Demonstrating Durable, Tunable Bidirectional Regulation Of Gene Expression In Cellular Models At Pre-transcriptional Level At The American Society Of Gene And Cell Therapy Annual Meeting

Chat with this insight

Recent Analyst Ratings for $OMGA

$OMGA SEC Filings

Omega Therapeutics Inc. filed SEC Form 8-K: Other Events

SEC Form 10-Q filed by Omega Therapeutics Inc.

Omega Therapeutics Inc. filed SEC Form 8-K: Leadership Update

$OMGA Financials

Live finance-specific insights

Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial

Omega Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial on September 26

$OMGA Leadership Updates

Live Leadership Updates

$OMGA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies

Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results

Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio

Omega Therapeutics downgraded by Raymond James

Raymond James initiated coverage on Omega Therapeutics with a new price target

Jefferies resumed coverage on Omega Therapeutics with a new price target

$OMGA Press Releases

Fastest customizable press release news feed in the world

Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies

Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer

Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results

$OMGA Market Insights

Live Market Insights

$OMGA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Omega Therapeutics shares are trading higher after Raymond James initiated coverage on the stock with an Outperform rating and announced a $12 price target.

Expert Ratings For Omega Therapeutics

Raymond James Initiates Coverage On Omega Therapeutics with Outperform Rating, Announces Price Target of $12

SEC Form 4 filed by Officer Certel Kaan

SEC Form 4 filed by Director Rosiello Robert L.

SEC Form 3 filed by new insider Rosiello Robert L.

$OMGA Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Omega Therapeutics Inc. (Amendment)

SEC Form SC 13G/A filed by Omega Therapeutics Inc. (Amendment)

SEC Form SC 13G/A filed by Omega Therapeutics Inc. (Amendment)

Recent Analyst Ratings for
$OMGA

$OMGA
SEC Filings

$OMGA
Financials

$OMGA
Leadership Updates

$OMGA
Analyst Ratings

$OMGA
Press Releases

$OMGA
Market Insights

$OMGA
Insider Trading

$OMGA
Large Ownership Changes